News
NVTA
--
0.00%
--
BRIEF-Invitae To Open New Facility In North Carolina To Support Continued Growth
reuters.com · 14h ago
Invitae to Open New Facility in North Carolina to Support Continued Growth
SAN FRANCISCO, April 20, 2021 /PRNewswire via COMTEX/ -- SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical...
PR Newswire - PRF · 14h ago
Invitae to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
SAN FRANCISCO, April 20, 2021 /PRNewswire via COMTEX/ -- SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical...
PR Newswire - PRF · 22h ago
BRIEF-Astrazeneca, Loxo Oncology At Lilly, And Invitae Corp Join Access To Comprehensive Genomic Profiling Coalition
reuters.com · 1d ago
AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation Join the Access to Comprehensive Genomic Profiling Coalition
The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation (NYSE: NVTA) to its coalition of companies advocating for appropriate coverage of comprehensive geno...
PR Newswire · 1d ago
Insights on the Solid Tumor Testing Global Market to 2030 - Focus on Technology, Cancer Type, Application, End-user and Competitive Landscape
Dublin, April 19, Apr 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Global Solid Tumor Testing Market 2019-2030:...
GlobeNewswire · 2d ago
Invitae (NVTA) Receives a Buy from Oppenheimer
Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Invitae (NVTA) yesterday and set a price target of $48.00. The company's shares closed last
SmarterAnalyst · 5d ago
Insider Trends: 90-Days of Insider Buying at Invitae Interrupted with Share Disposition
MT Newswires · 5d ago
Study finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer
, /PRNewswire/ --  (NYSE: NVTA), a leading medical genetics company, today announced research showing one in six people with colorectal cancer harbor genetic changes that are known to substantially increase the risk for cancer, especially in patients who ...
PR Newswire - PRF · 5d ago
Invitae (NVTA) Dips More Than Broader Markets: What You Should Know
Zacks · 6d ago
Cathie Wood sees these 2 trends as the next big things after electric vehicles
Wood has big bets on names like Square and PayPal, which dominate the digital wallet space.
CNBC.com · 04/14 00:28
Hereditary Cancer Testing Market Share, Growth, PESTL, Posters Five Analysis 2021-2025
Apr 13, 2021 (Market Insight Reports) -- This research service provides a strategic analysis of the Hereditary Cancer Testing Market 2021-2025. Based on...
Market Insight Reports · 04/13 18:22
Hematologic Malignancies Testing Market Analysis, Key Company Profiles, Types, Applications and Forecast To 2027
Apr 13, 2021 (Market Insight Reports) -- The rising prevalence of Leukemia and Multiple myeloma and the increasing awareness among patients and healthcare...
Market Insight Reports · 04/13 15:21
Do Institutions Own Invitae Corporation (NYSE:NVTA) Shares?
The big shareholder groups in Invitae Corporation ( NYSE:NVTA ) have power over the company. Large companies usually...
Simply Wall St. · 04/13 10:08
Ark Invest analyst says these are two of the firm's favorite genomic revolution plays
In a CNBC interview, Ark Invest analyst Simon Barnett explains the firm's belief in Adaptive Biotechnologies and Invitae.
CNBC.com · 04/12 22:29
We're really excited that these genomics companies, says Ark's Simon Barnett
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
CNBC.com · 04/12 22:28
Invitae one of our highest conviction names, says Ark's Simon Barnett
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
CNBC.com · 04/12 22:16
How a Simple Blood Test Could Reduce Cancer Deaths
Liquid biopsies and genomic sequencing that track cancer-related DNA have spawned start-ups and produced eye-popping projections on Wall Street. The diagnostic technology is cutting edge, and the industry is very young.
Barrons.com · 04/12 11:26
Outlook on the Precision Psychiatry Global Market to 2026 - Increasing Adoption of Inorganic Growth Strategies is Driving Growth
Dublin, April 09, Apr 09, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, April 09, 2021 (GLOBE NEWSWIRE) -- The "Global Precision Psychiatry Market: Focus on...
GlobeNewswire · 04/09 11:59
Genomics Personalized Health Market Size and Share 2021 to 2026 Market Segmentationby Product Type Level, Industry Level, Analysis of COVID-19 Impact
Apr 09, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" “Genomics Personalized Health Market”...
The Express Wire · 04/09 09:15
Webull provides a variety of real-time NVTA stock news. You can receive the latest news about Invitae through multiple platforms. This information may help you make smarter investment decisions.
About NVTA
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.